8月14日，联影医疗今日收盘127.92元，下跌2.38%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到83.10倍，总市值1054.26亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，联影医疗排 名第103位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13联影医疗83.1083.555.201054.26亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18.2218.241.5139.27亿9奥泰生物18.4419.441.4958.81亿10维力医疗18.4719.732.3243.29亿11鱼跃医疗 20. ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of United Imaging Healthcare, indicating a high price-to-earnings (PE) ratio compared to industry averages [1][2] - As of August 8, the company's stock closed at 130.7 yuan, with a PE ratio of 84.91, significantly higher than the industry average of 55.70 and median of 39.08 [1][2] - The total market capitalization of United Imaging Healthcare is reported at 107.17 billion yuan [1][2] Group 2 - For Q1 2025, the company achieved a revenue of 2.478 billion yuan, reflecting a year-on-year growth of 5.42%, and a net profit of 370 million yuan, with a year-on-year increase of 1.87% [2] - The company's gross profit margin stands at 49.94% [2] - As of March 31, 2025, the number of shareholders increased to 21,435, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of United Imaging Healthcare, with a focus on its stock performance and industry comparisons [1][2] - As of June 20, the company's stock closed at 128.46 yuan, with a 1.05% increase, resulting in a rolling PE ratio of 83.45 times and a total market capitalization of 105.87 billion yuan [1] - The average PE ratio for the medical device industry is 47.91 times, with a median of 35.05 times, positioning United Imaging Healthcare at the 105th rank within the industry [1][2] Group 2 - For the first quarter of 2025, the company reported a revenue of 2.478 billion yuan, reflecting a year-on-year growth of 5.42%, and a net profit of 370 million yuan, with a year-on-year increase of 1.87% [2] - The company's gross profit margin stands at 49.94% [2] - United Imaging Healthcare has a total of 11,502 intellectual property applications, with 5,882 granted, and during the reporting period, it filed 1,079 new applications, receiving 707 approvals, including 766 invention patent applications and 465 granted [1]

Investment Rating - The report assigns a "Hold" rating for the company, indicating a cautious approach towards investment in the current market conditions [5]. Core Insights - The company has established itself as a leader in the domestic medical imaging equipment market, with a strong focus on innovation and global market penetration [3][4]. - The domestic market is expected to recover significantly starting from Q4 2024, driven by large-scale equipment upgrades and a favorable policy environment [4]. - The company is actively expanding its product line, including the introduction of groundbreaking products and the integration of AI technologies, which are expected to enhance its competitive edge [5][40]. Summary by Sections Company Overview - Founded in 2011, the company has rapidly developed a comprehensive product line in medical imaging, radiation therapy, and life sciences, achieving leading market shares in MR, CT, PET, and DR categories [3][17]. - The company has established regional headquarters and R&D centers in various countries, enhancing its global presence and collaboration with international partners [17]. Market Trends - The global medical imaging equipment market is projected to exceed $60 billion by 2030, with the domestic market expected to reach over 100 billion yuan [48][53]. - The company is well-positioned to benefit from the increasing demand for high-end medical imaging equipment, as domestic brands gradually replace imported products [67]. Financial Performance - The company has shown a compound annual growth rate (CAGR) of over 25% in revenue from 2020 to 2023, with a significant recovery in net profit following a period of losses [23][28]. - Revenue from medical imaging equipment sales constitutes approximately 87% of total revenue, with CT and MR products accounting for nearly 70% of sales [28][30]. Innovation and R&D - The company invests heavily in R&D, with an average of 19.63% of revenue allocated to research activities from 2018 to 2023, positioning it among the leaders in the industry [40][42]. - The company has developed a robust patent portfolio, with over 4,134 authorized patents, ensuring a strong competitive position in the market [47]. Product Development - The company has launched several innovative products, including the uMR Jupiter 5T and uLinac HalosTx, which have received high industry recognition [5][71]. - The integration of AI technologies into its product offerings is expected to create new business opportunities and enhance operational efficiency [5][71].